CVS Health Corp vs KKR & Co Inc — how do they compare? CVS Health Corp trades at $85.46 (market cap $112.29B), while KKR & Co Inc trades at $90 (market cap $80.39B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and KKR & Co Inc for 67 Days on average.
| CVS | KKR | |
|---|---|---|
Market Cap | $112.29B | $80.39B |
Volume | 7,763,676 | 6,517,705 |
Sector | Health | Financials |
52-Week High | $110.60 | $142.75 |
52-Week Low | $70.08 | $83.88 |
Typical Hold Time | 83 Days | 67 Days |
Enterprise Value | $174.64B | $2.95B |
Dividend Yield | 3.03% | 0.87% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
KKR trades at $89.67, down 1.1% on the day, with a bearish technical signal but strong analyst support. Recent earnings show beats in Q1 and Q2 2026, with revenue of $19.21B in 2025 and net income of $2.37B. The stock is supported by a consensus price target of $123.30, indicating significant upside potential. News highlights active deal-making, including joint ventures and asset sales, reinforcing its global investment firm strategy.
The outlook for KKR is positive based on robust fundamentals and analyst optimism, though technical indicators suggest near-term caution. Investment opportunities include potential price appreciation toward the consensus target and ongoing strategic investments. Risks involve market volatility, execution of large-scale deals, and macroeconomic factors affecting asset management returns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →